This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.64% per year. These returns cover a period from January 1, 1988 through August 4, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Why Should You Add Horace Mann (HMN) Stock to Your Portfolio?
by Zacks Equity Research
Focus on improving product offerings, strengthening distribution, and modernizing infrastructure bode well for Horace Mann Educators (HMN).
Old Republic (ORI) Rises 15% in a Year: More Upside Left?
by Zacks Equity Research
Solid market presence, niche focus, low property catastrophe exposure at its General Insurance segment and solid capital position continue to drive Old Republic (ORI).
Brown & Brown (BRO) Up 35% in a Year: More Upside Left?
by Zacks Equity Research
Strong performing segments, strategic buyouts to capitalize on growing markets opportunities, sturdy financial standing and effective capital deployment continue to drive Brown & Brown (BRO).
Reasons Why Investors Should Retain Radian Group (RDN) Stock
by Zacks Equity Research
Radian Group (RDN) is poised to grow due to growth in the purchase market, lower refinance activity as well as financial flexibility.
Reasons Why You Should Retain MGIC Investment (MTG) Stock
by Zacks Equity Research
MGIC Investment (MTG) is poised to grow due to lower ceded premiums written, a decreasing delinquency rate, a lower leverage ratio and effective capital deployment.
MetLife's (MET) Structured Solution to Offer Financial Security
by Zacks Equity Research
MetLife (MET) launches a Structured Installment Sale solution with an aim to offer a guaranteed periodic income and defer tax liability of the sellers of qualified properties.
Horace Mann (HMN) to Share More Profits, Raises Dividend
by Zacks Equity Research
Horace Mann's (HMN) recent dividend hike reflects solid financial foundation and operational performance.
Best Income Stocks to Buy for March 8th
by Zacks Equity Research
HMN, BAK, and LCNB made it to the Zacks Rank #1 (Strong Buy) income stocks list on March 8, 2022.
Zacks.com featured highlights include Meridian Bioscience, Innoviva, Horace Mann Educators and Maravai LifeSciences
by Zacks Equity Research
Meridian Bioscience, Innoviva, Horace Mann Educators and Maravai LifeSciences are included in this blog.
Hartford Financial's (HIG) New Product Expands Coverage
by Zacks Equity Research
Hartford Financial (HIG) introduces a critical illness insurance product covering over 160 health conditions and offers benefits to employees depending on the intensity of disease.
Sail Through the Choppy Market With These 4 Low-Beta Stocks
by Nilanjan Banerjee
It is imperative to build a portfolio of low-beta stocks to sail through a choppy market. Meridian (VIVO), Innoviva (INVA), Horace (HMN) and Maravai LifeSciences (MRVI) are well poised to gain.
Aflac (AFL) Ties Up to Cater to Employees' Mental Health Issues
by Zacks Equity Research
Aflac (AFL) teams up with NeuroFlow for integrating a mental health solution into AFL's Group Long-Term Disability offering, thereby aiming to address employees' behavioral health challenges.
After Golden Cross, Horace Mann (HMN)'s Technical Outlook is Bright
by Zacks Equity Research
Is it a good or bad thing when a stock experiences a golden cross technical event?
Prudential Financial (PRU) Up 27.3% in a Year: More Room to Run?
by Zacks Equity Research
Prudential Financial (PRU) stock soars on the back of higher variable investment income, cost savings initiatives and effective capital deployment.
MetLife (MET) Offers Employers Aura's Digital Security Solutions
by Zacks Equity Research
MetLife (MET) forges an alliance with Aura to safeguard the digital identity of employees, having access to its U.S. Group Benefits platform, with the latter's solutions.
Assurant (AIZ) Up 30.7% in a Year: More Room for Growth?
by Zacks Equity Research
Assurant (AIZ) stock soars on the back of continued mobile subscriber growth, higher trade-in volumes and effective capital deployment.
Are These Finance Stocks a Great Value Stocks Right Now?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
EverQuote (EVER) Q4 Earnings and Revenues Beat Estimates
by Zacks Equity Research
EverQuote's (EVER) Q4 results reflect growth in the Variable Marketing Margin and a solid performance in the other insurance vertical.
MetLife (MET) Extends Solution to Aid Bangladesh Consumers
by Zacks Equity Research
MetLife (MET) launches its cutting-edge 360Health solution in Bangladesh with an aim to empower the country's customers to effectively tackle critical illnesses.
Should Value Investors Buy These Finance Stocks?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Horace Mann (HMN) Q4 Earnings Beat on Retirement Unit Strength
by Zacks Equity Research
Horace Mann's (HMN) fourth-quarter results reflect improved net investment income and strong performance exhibited by the Retirement unit, partly offset by elevated operating costs.
Horace Mann (HMN) Beats Q4 Earnings and Revenue Estimates
by Zacks Equity Research
Horace Mann (HMN) delivered earnings and revenue surprises of 34.72% and 0.91%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Earnings Preview: Horace Mann (HMN) Q4 Earnings Expected to Decline
by Zacks Equity Research
Horace Mann (HMN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Horace Mann (HMN) Surpasses Q3 Earnings Estimates
by Zacks Equity Research
Horace Mann (HMN) delivered earnings and revenue surprises of 8.70% and -0.38%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
Earnings Preview: Horace Mann (HMN) Q3 Earnings Expected to Decline
by Zacks Equity Research
Horace Mann (HMN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.